Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial

Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, for UC detection and evaluated its clinical feasibility. The prediction model was developed...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 23; no. 1; pp. 57 - 6
Main Authors Wu, Junlong, Lin, Yuda, Yang, Kaiwei, Liu, Xiao, Wang, Huina, Yu, Tingting, Tao, Ran, Guo, Jing, Chen, Libin, Cheng, Huanqing, Lou, Feng, Cao, Shanbo, Yu, Wei, Hu, Hailong, Ye, Dingwei
Format Journal Article
LanguageEnglish
Published London BioMed Central 19.03.2024
BioMed Central Ltd
BMC
Subjects
Accuracy
Algorithms
Biomedical and Life Sciences
Biomedicine
Bladder
Cancer
Cancer biomarkers
Cancer Research
Carcinoma
Cellular biology
Clinical trials
Correspondence
Cytology
Diagnosis
DNA
drug resistance
Early detection
Fibroblast growth factor receptors
Genetic aspects
Hematuria
Latest Correspondence on Biomarkers for Cancer diagnosis
Liquid biopsy
Malignancy
Medical prognosis
Methylation
Molecular diagnosis
Mutation
Oncology
Patient compliance
Prediction models
prognosis
Sensitivity analysis
Tumors
Urinary tract
Urine
Urine tumor DNA
Urological cancer
Urothelial carcinoma
Cancer biomarkers
Liquid biopsy
Molecular diagnosis
Urothelial carcinoma
Urine tumor DNA
Early detection
Online AccessGet full text
ISSN1476-4598
1476-4598
DOI10.1186/s12943-024-01974-4

Cover

Abstract Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, for UC detection and evaluated its clinical feasibility. The prediction model was developed in a retrospective cohort ( n  = 382), integrating assays for FGFR3 and TERT mutations and aberrant ONECUT2 and VIM methylation to generate a UC-score. The test performance was validated in a double-blinded, multicenter, prospective trial ( n  = 947; ChiCTR2300076543) and demonstrated a sensitivity of 91.37% and a specificity of 95.09%. The sensitivity reached 75.81% for low-grade Ta tumors and exceeded 93% in high-grade Ta and higher stages (T1 to T4). Simultaneous identification of both bladder and upper urinary tract tumors was enabled with sensitivities exceeding 90%. No significant confounding effects were observed regarding benign urological diseases or non-UC malignancies. The test showed improved sensitivities over urine cytology, the NMP22 test, and UroVysion FISH alongside comparable specificities. The single-target accuracy was greater than 98% as confirmed by Sanger sequencing. Post-surgery UC-score decreased in 97.7% of subjects. Overall, UI-Seek demonstrated robust performance and considerable potential for the early detection of UC.
AbstractList Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, for UC detection and evaluated its clinical feasibility. The prediction model was developed in a retrospective cohort (n = 382), integrating assays for FGFR3 and TERT mutations and aberrant ONECUT2 and VIM methylation to generate a UC-score. The test performance was validated in a double-blinded, multicenter, prospective trial (n = 947; ChiCTR2300076543) and demonstrated a sensitivity of 91.37% and a specificity of 95.09%. The sensitivity reached 75.81% for low-grade Ta tumors and exceeded 93% in high-grade Ta and higher stages (T1 to T4). Simultaneous identification of both bladder and upper urinary tract tumors was enabled with sensitivities exceeding 90%. No significant confounding effects were observed regarding benign urological diseases or non-UC malignancies. The test showed improved sensitivities over urine cytology, the NMP22 test, and UroVysion FISH alongside comparable specificities. The single-target accuracy was greater than 98% as confirmed by Sanger sequencing. Post-surgery UC-score decreased in 97.7% of subjects. Overall, UI-Seek demonstrated robust performance and considerable potential for the early detection of UC.
Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, for UC detection and evaluated its clinical feasibility. The prediction model was developed in a retrospective cohort (n = 382), integrating assays for FGFR3 and TERT mutations and aberrant ONECUT2 and VIM methylation to generate a UC-score. The test performance was validated in a double-blinded, multicenter, prospective trial (n = 947; ChiCTR2300076543) and demonstrated a sensitivity of 91.37% and a specificity of 95.09%. The sensitivity reached 75.81% for low-grade Ta tumors and exceeded 93% in high-grade Ta and higher stages (T1 to T4). Simultaneous identification of both bladder and upper urinary tract tumors was enabled with sensitivities exceeding 90%. No significant confounding effects were observed regarding benign urological diseases or non-UC malignancies. The test showed improved sensitivities over urine cytology, the NMP22 test, and UroVysion FISH alongside comparable specificities. The single-target accuracy was greater than 98% as confirmed by Sanger sequencing. Post-surgery UC-score decreased in 97.7% of subjects. Overall, UI-Seek demonstrated robust performance and considerable potential for the early detection of UC. Keywords: Liquid biopsy, Urine tumor DNA, Cancer biomarkers, Molecular diagnosis, Early detection, Urothelial carcinoma
Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, for UC detection and evaluated its clinical feasibility. The prediction model was developed in a retrospective cohort (n = 382), integrating assays for FGFR3 and TERT mutations and aberrant ONECUT2 and VIM methylation to generate a UC-score. The test performance was validated in a double-blinded, multicenter, prospective trial (n = 947; ChiCTR2300076543) and demonstrated a sensitivity of 91.37% and a specificity of 95.09%. The sensitivity reached 75.81% for low-grade Ta tumors and exceeded 93% in high-grade Ta and higher stages (T1 to T4). Simultaneous identification of both bladder and upper urinary tract tumors was enabled with sensitivities exceeding 90%. No significant confounding effects were observed regarding benign urological diseases or non-UC malignancies. The test showed improved sensitivities over urine cytology, the NMP22 test, and UroVysion FISH alongside comparable specificities. The single-target accuracy was greater than 98% as confirmed by Sanger sequencing. Post-surgery UC-score decreased in 97.7% of subjects. Overall, UI-Seek demonstrated robust performance and considerable potential for the early detection of UC.Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, for UC detection and evaluated its clinical feasibility. The prediction model was developed in a retrospective cohort (n = 382), integrating assays for FGFR3 and TERT mutations and aberrant ONECUT2 and VIM methylation to generate a UC-score. The test performance was validated in a double-blinded, multicenter, prospective trial (n = 947; ChiCTR2300076543) and demonstrated a sensitivity of 91.37% and a specificity of 95.09%. The sensitivity reached 75.81% for low-grade Ta tumors and exceeded 93% in high-grade Ta and higher stages (T1 to T4). Simultaneous identification of both bladder and upper urinary tract tumors was enabled with sensitivities exceeding 90%. No significant confounding effects were observed regarding benign urological diseases or non-UC malignancies. The test showed improved sensitivities over urine cytology, the NMP22 test, and UroVysion FISH alongside comparable specificities. The single-target accuracy was greater than 98% as confirmed by Sanger sequencing. Post-surgery UC-score decreased in 97.7% of subjects. Overall, UI-Seek demonstrated robust performance and considerable potential for the early detection of UC.
Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, for UC detection and evaluated its clinical feasibility. The prediction model was developed in a retrospective cohort ( n  = 382), integrating assays for FGFR3 and TERT mutations and aberrant ONECUT2 and VIM methylation to generate a UC-score. The test performance was validated in a double-blinded, multicenter, prospective trial ( n  = 947; ChiCTR2300076543) and demonstrated a sensitivity of 91.37% and a specificity of 95.09%. The sensitivity reached 75.81% for low-grade Ta tumors and exceeded 93% in high-grade Ta and higher stages (T1 to T4). Simultaneous identification of both bladder and upper urinary tract tumors was enabled with sensitivities exceeding 90%. No significant confounding effects were observed regarding benign urological diseases or non-UC malignancies. The test showed improved sensitivities over urine cytology, the NMP22 test, and UroVysion FISH alongside comparable specificities. The single-target accuracy was greater than 98% as confirmed by Sanger sequencing. Post-surgery UC-score decreased in 97.7% of subjects. Overall, UI-Seek demonstrated robust performance and considerable potential for the early detection of UC.
Abstract Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, for UC detection and evaluated its clinical feasibility. The prediction model was developed in a retrospective cohort (n = 382), integrating assays for FGFR3 and TERT mutations and aberrant ONECUT2 and VIM methylation to generate a UC-score. The test performance was validated in a double-blinded, multicenter, prospective trial (n = 947; ChiCTR2300076543) and demonstrated a sensitivity of 91.37% and a specificity of 95.09%. The sensitivity reached 75.81% for low-grade Ta tumors and exceeded 93% in high-grade Ta and higher stages (T1 to T4). Simultaneous identification of both bladder and upper urinary tract tumors was enabled with sensitivities exceeding 90%. No significant confounding effects were observed regarding benign urological diseases or non-UC malignancies. The test showed improved sensitivities over urine cytology, the NMP22 test, and UroVysion FISH alongside comparable specificities. The single-target accuracy was greater than 98% as confirmed by Sanger sequencing. Post-surgery UC-score decreased in 97.7% of subjects. Overall, UI-Seek demonstrated robust performance and considerable potential for the early detection of UC.
ArticleNumber 57
Audience Academic
Author Lin, Yuda
Yu, Wei
Hu, Hailong
Wu, Junlong
Ye, Dingwei
Cao, Shanbo
Liu, Xiao
Tao, Ran
Cheng, Huanqing
Wang, Huina
Yu, Tingting
Chen, Libin
Lou, Feng
Yang, Kaiwei
Guo, Jing
Author_xml – sequence: 1
  givenname: Junlong
  surname: Wu
  fullname: Wu, Junlong
  organization: Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
– sequence: 2
  givenname: Yuda
  surname: Lin
  fullname: Lin, Yuda
  organization: Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University
– sequence: 3
  givenname: Kaiwei
  surname: Yang
  fullname: Yang, Kaiwei
  organization: Department of Urology, Peking University First Hospital
– sequence: 4
  givenname: Xiao
  surname: Liu
  fullname: Liu, Xiao
  organization: Acornmed Biotechnology Co., Ltd
– sequence: 5
  givenname: Huina
  surname: Wang
  fullname: Wang, Huina
  organization: Acornmed Biotechnology Co., Ltd
– sequence: 6
  givenname: Tingting
  surname: Yu
  fullname: Yu, Tingting
  organization: Acornmed Biotechnology Co., Ltd
– sequence: 7
  givenname: Ran
  surname: Tao
  fullname: Tao, Ran
  organization: Acornmed Biotechnology Co., Ltd
– sequence: 8
  givenname: Jing
  surname: Guo
  fullname: Guo, Jing
  organization: Acornmed Biotechnology Co., Ltd
– sequence: 9
  givenname: Libin
  surname: Chen
  fullname: Chen, Libin
  organization: Acornmed Biotechnology Co., Ltd
– sequence: 10
  givenname: Huanqing
  surname: Cheng
  fullname: Cheng, Huanqing
  organization: Acornmed Biotechnology Co., Ltd
– sequence: 11
  givenname: Feng
  surname: Lou
  fullname: Lou, Feng
  email: fenglou@acornmed.com
  organization: Acornmed Biotechnology Co., Ltd
– sequence: 12
  givenname: Shanbo
  surname: Cao
  fullname: Cao, Shanbo
  email: shanbocao@acornmed.com
  organization: Acornmed Biotechnology Co., Ltd
– sequence: 13
  givenname: Wei
  surname: Yu
  fullname: Yu, Wei
  email: yuweif@126.com
  organization: Department of Urology, Peking University First Hospital
– sequence: 14
  givenname: Hailong
  surname: Hu
  fullname: Hu, Hailong
  email: huhailong@tmu.edu.cn
  organization: Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University
– sequence: 15
  givenname: Dingwei
  surname: Ye
  fullname: Ye, Dingwei
  email: dwyeli@163.com
  organization: Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38504268$$D View this record in MEDLINE/PubMed
BookMark eNqNUstu1DAUjVARfcAPsECR2LBoiu04dswGjYZXpQo2sLYc53rqkccenKSo38BPc6cpfQlVKItEN-ec-zjnsNiLKUJRvKTkhNJWvB0oU7yuCOMVoUryij8pDiiXouKNavfufO8Xh8OwJoTKVvJnxX7dNoQz0R4Uv5fBR29NKME5sKO_gAjDUCZXmnIzhdGPJq9gLKfsI5Qfvi7KEYaxdCljKY3nEDySrcnWx7QxZQ_jTibFdyjQp6kLUHXYo4f-eBa0EEfIx-U2p2E7tyzHjCrPi6fOhAFeXL-Pih-fPn5ffqnOvn0-XS7OKitIO1ZCuQ46xVUDvDMGCFGNrJmtDRENMYoL6njjTM1Y3zFppXEEWsWarieKcFkfFaezbp_MWm-z35h8qZPx-qqQ8kqbjHMG0MIBdUQis-k5x6tLShtV01pIhzWDWvWsNcWtufxlQrgRpETvbNKzTRpt0lc2aY6s9zNrO3Ub6HcXySbcG-X-n-jP9SpdoCbuLQRFhTfXCjn9nNARvfGDhRBMhDQNminJJOGNZAh9_QC6TlOOeGFdk3qXCNk2t6iVwb19dAkb252oXshWtFIJRhB18g8UPj1svMV4Oo_1e4RXdze9WfFvAhHAZoDFOAwZ3P_dr31AspjTXepwHB8ep14bNmCfuIJ8e41HWH8AY9YPTw
CitedBy_id crossref_primary_10_1016_j_urolonc_2025_02_009
crossref_primary_10_1111_bju_16450
crossref_primary_10_3892_ijo_2025_5724
Cites_doi 10.1186/s12885-022-09616-y
10.1016/j.eururo.2022.03.027
10.1016/j.eururo.2021.08.010
10.1016/j.eururo.2023.03.013
10.7554/eLife.32143
10.1097/JU.0000000000001297
10.1002/cncy.21327
10.1097/JU.0000000000001550
10.3390/ijms21186542
10.1016/j.juro.2016.09.118
10.1016/j.jmoldx.2023.05.003
10.1038/s41585-023-00773-8
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
COPYRIGHT 2024 BioMed Central Ltd.
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 BioMed Central Ltd.
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1186/s12943-024-01974-4
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
Publicly Available Content Database

CrossRef


PubMed
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 6
ExternalDocumentID oai_doaj_org_article_6fe1f07bd05d441187115931367fd05a
10.1186/s12943-024-01974-4
PMC10949661
A786879620
38504268
10_1186_s12943_024_01974_4
Genre Letter
GrantInformation_xml – fundername: Tianjin Institute of Urology Talent Funding Program
  grantid: MYSRC202310
– fundername: Tianjin Key Medical Discipline (Specialty) Construction Project
  grantid: TJYXZDXK-023A
– fundername: Tianjin Municipal Health Industry Key Project
  grantid: TJWJ2022XK014
– fundername: Scientific Research Project of Tianjin Municipal Education Commission
  grantid: 2022ZD069
– fundername: Zhaoyang Cancer Research Fund of The Chinese Society of Clinical Oncology
  grantid: Y-Young2023-0087
– fundername: Shanghai Municipal Health Bureau Project
  grantid: 2020CXJQ03
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
LGEZI
LOTEE
M1P
M48
M~E
NADUK
NXXTH
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
CITATION
ALIPV
NPM
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
7X8
5PM
2VQ
4.4
ADTOC
AHSBF
EJD
H13
IPNFZ
RIG
UNPAY
ID FETCH-LOGICAL-c608t-69fbeb9495e4baae0095732c3a0650a9461f45fa322db27c7af0e8925bd090473
IEDL.DBID 7X7
ISSN 1476-4598
IngestDate Wed Aug 27 01:08:17 EDT 2025
Wed Aug 20 00:14:24 EDT 2025
Tue Sep 30 17:09:49 EDT 2025
Thu Sep 04 19:36:23 EDT 2025
Sat Jul 26 00:17:40 EDT 2025
Tue Jun 17 22:17:46 EDT 2025
Tue Jun 10 21:08:43 EDT 2025
Mon Jul 21 05:39:06 EDT 2025
Thu Apr 24 23:00:12 EDT 2025
Wed Oct 01 01:45:29 EDT 2025
Sat Sep 06 07:32:25 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Cancer biomarkers
Liquid biopsy
Molecular diagnosis
Urothelial carcinoma
Urine tumor DNA
Early detection
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c608t-69fbeb9495e4baae0095732c3a0650a9461f45fa322db27c7af0e8925bd090473
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Correspondence-3
content type line 23
OpenAccessLink https://www.proquest.com/docview/3037874785?pq-origsite=%requestingapplication%
PMID 38504268
PQID 3037874785
PQPubID 42702
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_6fe1f07bd05d441187115931367fd05a
unpaywall_primary_10_1186_s12943_024_01974_4
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10949661
proquest_miscellaneous_2972704572
proquest_journals_3037874785
gale_infotracmisc_A786879620
gale_infotracacademiconefile_A786879620
pubmed_primary_38504268
crossref_primary_10_1186_s12943_024_01974_4
crossref_citationtrail_10_1186_s12943_024_01974_4
springer_journals_10_1186_s12943_024_01974_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-03-19
PublicationDateYYYYMMDD 2024-03-19
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-03-19
  day: 19
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Molecular cancer
PublicationTitleAbbrev Mol Cancer
PublicationTitleAlternate Mol Cancer
PublicationYear 2024
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References L Deng (1974_CR12) 2022; 22
M Babjuk (1974_CR1) 2022; 81
DA Barocas (1974_CR13) 2020; 204
1974_CR3
SU Springer (1974_CR7) 2018; 7
1974_CR5
1974_CR6
W Kessel KEMv, Beukers (1974_CR9) 2017; 197
M Mancini (1974_CR8) 2020; 21
SL Woldu (1974_CR14) 2021; 205
BP Rai (1974_CR4) 2022; 82
H Dimashkieh (1974_CR10) 2013; 121
M Roupret (1974_CR2) 2023; 84
TJ Oh (1974_CR11) 2023; 25
References_xml – volume: 22
  start-page: 510
  year: 2022
  ident: 1974_CR12
  publication-title: BMC Cancer
  doi: 10.1186/s12885-022-09616-y
– volume: 82
  start-page: 182
  year: 2022
  ident: 1974_CR4
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2022.03.027
– volume: 81
  start-page: 75
  year: 2022
  ident: 1974_CR1
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2021.08.010
– volume: 84
  start-page: 49
  year: 2023
  ident: 1974_CR2
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2023.03.013
– volume: 7
  start-page: e32143
  year: 2018
  ident: 1974_CR7
  publication-title: Elife
  doi: 10.7554/eLife.32143
– volume: 204
  start-page: 778
  year: 2020
  ident: 1974_CR13
  publication-title: J Urol
  doi: 10.1097/JU.0000000000001297
– volume: 121
  start-page: 591
  year: 2013
  ident: 1974_CR10
  publication-title: Cancer Cytopathol
  doi: 10.1002/cncy.21327
– volume: 205
  start-page: 1387
  year: 2021
  ident: 1974_CR14
  publication-title: J Urol
  doi: 10.1097/JU.0000000000001550
– volume: 21
  start-page: 6542
  year: 2020
  ident: 1974_CR8
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21186542
– volume: 197
  start-page: 590
  year: 2017
  ident: 1974_CR9
  publication-title: J Urol
  doi: 10.1016/j.juro.2016.09.118
– ident: 1974_CR3
– volume: 25
  start-page: 646
  year: 2023
  ident: 1974_CR11
  publication-title: J Mol Diagn
  doi: 10.1016/j.jmoldx.2023.05.003
– ident: 1974_CR5
– ident: 1974_CR6
  doi: 10.1038/s41585-023-00773-8
SSID ssj0017874
Score 2.4435055
Snippet Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we...
Abstract Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein,...
SourceID doaj
unpaywall
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 57
SubjectTerms Accuracy
Algorithms
Biomedical and Life Sciences
Biomedicine
Bladder
Cancer
Cancer biomarkers
Cancer Research
Carcinoma
Cellular biology
Clinical trials
Correspondence
Cytology
Diagnosis
DNA
drug resistance
Early detection
Fibroblast growth factor receptors
Genetic aspects
Hematuria
Latest Correspondence on Biomarkers for Cancer diagnosis
Liquid biopsy
Malignancy
Medical prognosis
Methylation
Molecular diagnosis
Mutation
Oncology
Patient compliance
Prediction models
prognosis
Sensitivity analysis
Tumors
Urinary tract
Urine
Urine tumor DNA
Urological cancer
Urothelial carcinoma
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5KoK9DadOX27SoUOiha-KHbEm9bR8hFJJTA7kJWZJpwLVDdpeQ35A_3Rn50XULaQ-9SrLweEYz33hGMwBv05pioomKHaKRmCMGiJXjOR68qvbSpcJ4chSPjsvDE_71tDjdavVFOWF9eeD-w-2Xtcf9ROWSwqHpThHgowXOqdJYjWMBGqEZG52pIX6AYsjHKzKy3F-hVeMUr6SMC0TQMZ-ZoVCt_0-dvGWUfk-YnKKm9-Hupj03V5emabYM08FDeDAgSrbsKXkEt3y7C7f7HpNXu3DnaIieP4broQhow_osjkHRsa5mhoXMwj4vnNEfeM8-Hy8ZAtE1Q1yLQ3RVq0FpZZbaD7XdD8OcX4dMrvYDbuC6TdX4uGqoAKNb9BsSKf5iwZDY8U4nC41CnsDJwZdvnw7joRlDbMtEruNS1ZWvFPpTnlfGeMJmIs9sbgjkGcXLtOZFbVBBuCoTVpg68VJlBXJOJVzkT2Gn7Vr_HBj3jntrhMms4-Rg2swWSllvUutFUUeQjrzRdqhUTg0zGh08Flnqnp8a-akDPzWP4P30zHlfp-PG1R-J5dNKqrEdBlDy9CB5-m-SF8E7EhhNmgBfz5rhQgMSSTW19FLIUgpVZkkEe7OVeILtfHoUOT1okJVGaEFCLGQRwZtpmp6krLjWd5uVzhSiT8TkIovgWS-hE0m5LMg9lhHImezOaJ7PtGffQ33xFF1-9ILTCBajmP96r5s-6mI6Cv_Agxf_gwcv4V4WTnUep2oPdtYXG_8KUeK6eh0Uwk_Ss1-Y
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zb9QwEB6VIq4HBOUKFGQkBA9sIIcTx0gILUdVIW2fWKlvlmM7gBSS7R6C_Q38aWZytYGq4tVOLDvzjf1NZjwD8CwsyCcaSN8iG_E5cgBfWh6j4uWFy2wotCNDcXaUHs755-PkeAf6cNvuA67ONe2ontR8Wb76dbJ9hwr_tlH4LH29wjOLkzeS4imQH_v8-eLEp8JS5IDtqmxcgst4WEUE_Bk_dTQgXnl_l-bcoUbnVZPW_9_N-8zp9Xdk5eBevQHXNtVCb3_qsjxzgh3cgpsd9WTTFiu3YcdVe3ClLUa53YOrs87Nfgd-d9lCS9aGe3Q7IqsLplkTgtgGkDP6Ve_Yx6MpQ8a6ZkiAsYnudJUIa2aoTlFV_9DMunUT8lW9wQFsvclL5-clZWq0k3ZAWopbThgutr_8yZqKIndhfvDpy4dDv6va4Js0yNZ-Kovc5RINL8dzrR2ROBFHJtbEBrXkaVjwpNC4k9g8EkboInCZjJLcBjLgIr4Hu1VduQfAuLPcGS10ZCwnS9REJpHSOB0aJ5LCg7CXjTJdSnOqrFGqxrTJUtXKU6E8VSNPxT14ObyzaBN6XPj0exL58CQl424a6uVX1em2SguHkBc4_8QiuwzRBkWSGFMyvALbtAcvCDCKQIzTM7q7-YCLpORbaiqyNBMyjQIP9kdPoqqbcXcPOdVrikIOQiAWWeLB06Gb3qTwucrVm5WKJNJUJO8i8uB-i9BhSXGWkB2deZCNsDta87in-v6tSUQeBihmJHgeTHqYn87roo86GVThP2Tw8OJVP4LrUaOvsR_KfdhdLzfuMRLFdf6kUfU_T9li8w
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BERQOCAqFQEFGQuLARuThxDa3ZaGqkNoTlXqzHNtRkUJSdbNC_Q38aWbyYgOogqtf8mQe_iYzHgO8jkuKiUYqdIhGQo4YIFSOp6h4Remli4Xx5Cgen-RHp_zzWXY2lMmhuzDb8ftY5u_WeB5xijRSrgRi35DfhFsZGl5K31vlqyligILHx0sxf503O3i6-vx_WuGtY-j3FMkpTnoPdjf1hbn6bqpq6yg6fAD3BwzJlj3TH8INX-_B7f5Vyas9uHM8xMsfwY-h7GfF-ryNwbSxpmSGdbmEfSY4o3_unn08WTKEni1DJItNdDmrQvlklh4cqptvhjnfdrlb9XtcwDWbovJhUVHJRbfoFyRS_OWCIbHjLU7WPQ3yGE4PP31ZHYXD8wuhzSPZhrkqC18o9KA8L4zxhMZEmtjUEKwziudxybPSoElwRSKsMGXkpUqywkUq4iLdh526qf1TYNw77q0RJrGOk0tpE5spZb2JrRdZGUA88kbboTY5PZFR6c5Hkbnu-amRn7rjp-YBvJ3mXPSVOa4d_YFYPo2kqtpdAwqbHpRU56VH2RW4_8whTIzRmUS0l1JVuxLbTABvSGA06T5uz5rhCgMSSVW09FLIXAqVJ1EAB7ORqLN23j2KnB5sxlojmCAhFjIL4NXUTTMpD672zWatE4V4E1G4SAJ40kvoRFIqM3KIZQByJrszmuc99dfzrqJ4jE4--r1xAItRzH_t67qPuphU4R948Oz_Vn8Od5NOf9MwVgew015u_AtEgG3xslP9n1UZUQ0
  priority: 102
  providerName: Springer Nature
Title Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial
URI https://link.springer.com/article/10.1186/s12943-024-01974-4
https://www.ncbi.nlm.nih.gov/pubmed/38504268
https://www.proquest.com/docview/3037874785
https://www.proquest.com/docview/2972704572
https://pubmed.ncbi.nlm.nih.gov/PMC10949661
https://molecular-cancer.biomedcentral.com/counter/pdf/10.1186/s12943-024-01974-4
https://doaj.org/article/6fe1f07bd05d441187115931367fd05a
UnpaywallVersion publishedVersion
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVFSB
  databaseName: Free Full-Text Journals in Chemistry
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: HH5
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: http://abc-chemistry.org/
  providerName: ABC ChemistRy
– providerCode: PRVADU
  databaseName: BioMedCentral
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: RBZ
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: KQ8
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: KQ8
  dateStart: 20020701
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: DOA
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: Academic Search Ultimate - eBooks
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: ABDBF
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: DIK
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: GX1
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: M~E
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: RPM
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Health & Medical Collection
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: M48
  dateStart: 20020701
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: Springer Nature HAS Fully OA
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: AAJSJ
  dateStart: 20021201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 1476-4598
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017874
  issn: 1476-4598
  databaseCode: C6C
  dateStart: 20021201
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bi9QwFA66i7cH0fVWXYcIgg9O2V7SpvFFZsddloEZRF3Yt5AmqQq1HeeC7G_wT3tOetmtwuDLDCRpyem55DvJyTmEvA4LPBMNhG8AjfgMMIAvDItB8fLCZibkyqKjOF-kZ-dsdpFctBtu6zassrOJzlCbWuMe-RGYWpAtxrPk_fKnj1Wj8HS1LaFxk-yHAFVQqvlF73CF-EB3USZLj9awtjE8tcS4C8DRPhssRi5n_7-W-drS9HfYZH92eo_c2VZLdflLleW15en0Abnf4ko6aQThIblhqwNyq6k0eXlAbs_bM_RH5HebCrSkTSxHa-5oXVBFXXxhEx1OcR_e0g-LCQU4uqGAbqEJL2yVILNUYxGiqv6hqLEbF89VvYMXmHqbl9bPS0zDaMbNC5EUuxpTILa72UlduZDH5Pz05Mv0zG9LMvg6DbKNn4oit7kAr8qyXCmLCI3HkY4VQj0lWBoWLCkUmAmTR1xzVQQ2E1GSm0AEjMdPyF5VV_YZocwaZrXiKtKGoZupI50Ioa0KteVJ4ZGw443Ubb5yLJtRSue3ZKls-CmBn9LxUzKPvO2fWTbZOnaOPkaW9yMx07ZrqFdfZau4Mi0syDOH-ScGoGMIDiYgwBgz3RXQpjzyBgVGoj2A6WnVXmsAIjGzlpzwLM24SKPAI4eDkaDHetjdiZxs7chaXkm9R1713fgkxsZVtt6uZSQAgwIy55FHnjYS2pMUZwk6yZlHsoHsDmge9lTfv7ks4yE4_uALhx4Zd2J-Na9dH3Xcq8J_8OD5bqpfkLuR09fYD8Uh2dustvYloMBNPnKqPiL7k8ns8wz-j08WHz9B6zSdjtzOCvzOWfYHOA1eFQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIigcEJRXoICRQBy6UfNw4gQJoYVSbWm3p1bam3EcB5BCsuxD1f4G_gu_kZm82oC04tKr7ViezMPf2OMZgFduRneiTmyniEZsjhjAjlPuo-IlmYlSVyhDjuL4JByd8c-TYLIBv9u3MBRW2drEylCnpaYz8j00tShbXETB--lPm6pG0e1qW0KjFosjszpHl23-7nAf-fva8w4-nX4c2U1VAVuHTrSwwzhLTBKjY2B4opQhkCF8T_uK0IqKeehmPMgUSnqaeEILlTkmir0gSZ3Y4cLHea_Bde47nHL1i0nn4Lm0wPZhThTuzXEv5XRLSnEeiNtt3tv8qhoB_-4El7bCv8M0u7va27C1LKZqda7y_NJ2eHAX7jQ4lg1rwbsHG6bYhht1ZcvVNtwcN3f29-FXk3o0Z3XsSGNeWZkxxap4xjoandG5v2H7J0OG8HfBEE1jEz0Qy1FHmKaiR0X5Q7HULKr4seItTpCWyyQ3dpJT2sd0UE9IpJjZgCGx7UtSVpUneQBnV8Ksh7BZlIV5DIyblButhPJ0ysmt1Z4O4lgb5WojgswCt-WN1E1-dCrTkcvKT4pCWfNTIj9lxU_JLdjtvpnW2UHWjv5ALO9GUmbvqqGcfZWNoZBhZlB_BK4_SBGquujQIuL0KbNehm3KgjckMJLsDy5Pq-YZBRJJmbzkUERhJOLQcyzY6Y1Eu6H73a3IycZuzeWFllnwsuumLykWrzDlci69GDEvegLCs-BRLaEdSX4UkFMeWRD1ZLdHc7-n-P6tymruOshmRIsWDFoxv1jXup866FThP3jwZD3VL2BrdDo-lseHJ0dP4ZZX6a5vu_EObC5mS_MMEegieV6pPYMvV21n_gAImJR_
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Jb9QwFLagFQUOCMoWKGAkJA5M1CxObHMbKKMy0BESVOrNcmwHkEIymskI9Tfwp3kvGxNAFVy9yc5b_L28xYQ8C3P0iQbSt4BGfAYYwJeWxSB4We6EDbl2aCieLNLjUzY_S862svibaPfeJdnmNGCVprI-XNq8FXGRHq7hlmLof8QICkDEPrtMdkUiUzC_dqfT-cf54EkAhmR9ssxfZ44upKZu_5_aeet6-j10cvCfXidXN-VSn3_XRbF1Rc1ukhsdtqTTlhlukUuu3CdX2tcmz_fJ3knnR79NfnTlQAvaxnN0Ko9WOdW0iTFsI8Qp_ot39GgxpQBJawoIF5owaasAvqUGHyIqq2-aWlc3MV3lS1jAVpuscH5WYClGO2kXxKO41YTCYfvsTto8GXKHnM7efHp97HfPMvgmDUTtpzLPXCbBsnIs09ohSuNxZGKNcE9LloY5S3INqsJmETdc54ETMkoyG8iA8fgu2Smr0t0nlDnLnNFcR8YyNDVNZBIpjdOhcTzJPRL2tFGmq1mOT2cUqrFdRKpaeiqgp2roqZhHXgxzlm3FjgtHv0KSDyOx2nbTUK0-q054VZo74GkO-08swMcQjExAgTFWu8uhTXvkOTKMQp0A2zO6S22AQ2J1LTXlIhVcplHgkYPRSJBlM-7uWU51umStAGQgE3OReOTp0I0zMT6udNVmrSIJOBTQOY88cq_l0OFIsUjQUBYeESPeHZ153FN-_dJUGg_B-Ad7OPTIpGfzX_u66KNOBlH4Bxo8-L_Vn5C9D0cz9f7t4t1Dci1qRDn2Q3lAdurVxj0CkFhnjzs98BMrqF24
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+effectiveness+of+a+multitarget+urine+DNA+test+for+urothelial+carcinoma+detection%3A+a+double-blinded%2C+multicenter%2C+prospective+trial&rft.jtitle=Molecular+cancer&rft.au=Wu%2C+Junlong&rft.au=Lin%2C+Yuda&rft.au=Yang%2C+Kaiwei&rft.au=Liu%2C+Xiao&rft.date=2024-03-19&rft.pub=BioMed+Central&rft.eissn=1476-4598&rft.volume=23&rft.spage=1&rft_id=info:doi/10.1186%2Fs12943-024-01974-4
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon